ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- MetastasesCancer
- Registration Number
- NCT00034463
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Histologic or cytologic diagnosis of metastatic or locally advanced cancer
- Prior chemotherapy is allowed
- Adequate bone marrow, liver and kidney function
Exclusion Criteria
- Prior treatment with ALIMTA
- Brain metastasis
- Pregnancy or breast feeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
🇺🇸San Antonio, Texas, United States